CAMP4 Therapeutics Corporation Other Nonoperating Expense
CAMP4 Therapeutics Corporation (CAMP) reported Other Nonoperating Expense of $192.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingExpense · last filed 2026-03-05
- CAMP4 Therapeutics Corporation other nonoperating expense for the quarter ending 2024-12-31 was -$145.00K, a 274.70% decline year-over-year.
- CAMP4 Therapeutics Corporation other nonoperating expense for the quarter ending 2024-09-30 was $62.00K, a 31.91% increase year-over-year.
- CAMP4 Therapeutics Corporation other nonoperating expense for the quarter ending 2023-12-31 was $83.00K.
- CAMP4 Therapeutics Corporation other nonoperating expense for the quarter ending 2023-09-30 was $47.00K.
- CAMP4 Therapeutics Corporation other nonoperating expense for fiscal 2025 was $192.00K, a 481.82% increase from fiscal 2024.
- CAMP4 Therapeutics Corporation other nonoperating expense for fiscal 2024 was $33.00K, a 85.00% decline from fiscal 2023.
- CAMP4 Therapeutics Corporation other nonoperating expense for fiscal 2023 was $220.00K.
| Period end | Other Nonoperating Expense 3 month | Other Nonoperating Expense 6 month | Other Nonoperating Expense 9 month | Other Nonoperating Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $192.00K 10-K · filed 2026-03-05 | |||
| 2024-12-31 | -$145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$83.00K derived: sum of 2 quarters · filed 2026-03-05 | $33.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $62.00K 10-Q · filed 2024-11-21 | $178.00K 10-Q · filed 2024-11-21 | ||
| 2023-12-31 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $130.00K derived: sum of 2 quarters · filed 2025-03-27 | $220.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $47.00K 10-Q · filed 2024-11-21 | $137.00K 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |